This company provides tools for discovering and engineering bacteriophages, offering solutions for researchers and companies working with phage-based therapies and applications. Their products enable efficient phage isolation, characterization, and modification for targeted bacterial control.
Funding
Funding not disclosed
Founders
Product
Problem
The increasing threat of antimicrobial resistance demands faster, more affordable, and scalable solutions for developing phage-based therapies. Traditional phage discovery and engineering methods can be slow, expensive, and lack the precision needed for targeted bacterial control.
Solution
Biophoundry provides tools and technologies to accelerate the discovery and engineering of bacteriophages for therapeutic, diagnostic, and biomolecular engineering applications. Their platform leverages synthetic biology, robotics, and data science to enable rapid phage isolation, characterization, and modification. By harnessing the unique properties of phages, Biophoundry aims to deliver faster, more precise, and scalable solutions to combat antimicrobial resistance and redefine the future of molecular biology.
Target Audience
Biophoundry's primary customers are researchers and companies involved in developing phage-based therapies, diagnostics, and other applications requiring targeted bacterial control.
Features
- SpyPhage Platform for rapid, cell-free bacteriophage production
- Phax Platform for phage discovery and engineering
- Expertise in synthetic biology, robotics, and data science
- Capabilities in phage isolation, characterization, and modification
- Development of precision antibiotics and phage-based technologies